New combo therapy shows promise for common lung cancer mutation
NCT ID NCT06376084
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 20 times
Summary
This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutated non-small cell lung cancer. About 532 adults with stage IIIB, IIIC, or IV lung cancer that cannot be surgically removed are being observed in real-world clinics. The main goal is to see how long it takes for the cancer to grow or for the patient to die.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Shanghai, China
Conditions
Explore the condition pages connected to this study.